Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

S Ko, Jennifer; H Zea, Arnold; I Rini, Brian; L Ireland, Joanna; Elson, Paul; Cohen, Peter; Golshayan, Ali; A Rayman, Patricia; Wood, Laura; Garcia, Jorge; Dreicer, Robert; Bukowski, Ronald; H Finke, James

doi:10.1158/1078-0432.ccr-08-1332

Public

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.

Shared by NobleBlocks on Mar 15, 2009 • 12:00 AM UTC

Authors:

Jennifer S Ko

Arnold H Zea

Brian I Rini

Abstract

PURPOSE: Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induce T-cell suppression. Several factors pivotal to the accumulation of MDSC are targeted by the tyrosine...

Discussions